Direct and indirect costs for systemic lupus erythematosus in Sweden. A nationwide health economic study based on five defined cohorts

Seminars in Arthritis and Rheumatism

Volumn 45, Issue 6, 2016, Pages 684-690

  Jönsen, Andreas ^a   Hjalte, Frida ^b   Willim, Minna ^a   Carlsson, Katarina Steen ^b   Sjöwall, Christopher ^c   Svenungsson, Elisabet ^d   Leonard, Dag ^e   Bengtsson, Christine ^f   Rantapää Dahlqvist, Solbritt ^f   Pettersson, Susanne ^d   Gunnarsson, Iva ^d   Zickert, Agneta ^d   Gustafsson, Johanna T ^d   Rönnblom, Lars ^e   Petersson, Ingemar F ^a,g   Bengtsson, Anders A ^a   Nived, Ola ^a  

^a LUND UNIVERSITY   (Sweden)

^b SWEDISH INSTITUTE FOR HEALTH ECONOMICS   (Sweden)

^c LINKÖPING UNIVERSITY   (Sweden)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e UPPSALA UNIVERSITY   (Sweden)

^f UMEÅ UNIVERSITY   (Sweden)

^g LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Direct and indirect costs; Health economics; Systemic lupus erythematosus

Indexed keywords

CYCLOPHOSPHAMIDE; ILOPROST; RITUXIMAB;

ABSENTEEISM; ADULT; AGE DISTRIBUTION; ARTHRITIS; ARTICLE; COST BENEFIT ANALYSIS; DISEASE ACTIVITY; DISEASE DURATION; FEMALE; GLOMERULONEPHRITIS; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; OUTPATIENT CARE; PENSION; PREVALENCE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RASH; SLEDAI; SWEDEN; SYSTEMIC LUPUS ERYTHEMATOSUS; ADOLESCENT; AGED; AMBULATORY CARE; CHILD; COHORT ANALYSIS; DRUG COST; ECONOMICS; HOSPITALIZATION; LUPUS ERYTHEMATOSUS, SYSTEMIC; MEDICAL LEAVE; MIDDLE AGED; PRESCHOOL CHILD; REGISTER; RETROSPECTIVE STUDY; RHEUMATOLOGY; SEVERITY OF ILLNESS INDEX; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMBULATORY CARE; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DRUG COSTS; FEMALE; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; REGISTRIES; RETROSPECTIVE STUDIES; RHEUMATOLOGY; SEVERITY OF ILLNESS INDEX; SICK LEAVE; SWEDEN; YOUNG ADULT;

EID: 84951955210     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2015.11.013     Document Type: Article

References (35)

1. Gladman D.D., Urowitz M.B., Rahman P., Ibañez D., Tam L.S. Accrual of organ damage over time in patients with systemic lupus erythematosus. J Rheumatol 2003, 30:1955-1959.
2. Ståhl-Hallengren C., Jönsen A., Nived O., Sturfelt G. Incidence studies of systemic lupus erythematosus in Southern Sweden: increasing age, decreasing frequency of renal manifestations and good prognosis. J Rheumatol 2000, 27:685-691.
3. Zhu T.Y., Tam L.S., Li E.K. Cost-of-illness studies in systemic lupus erythematosus: a systematic review. Arthritis Care Res 2011, 63:751-760.
4. Johannesson M. Theory and methods of economic evaluation of health care. Dev Health Econ Public Policy 1996, 4:1-245.
5. Drummond MF, Schulper MJ, Torrance GW, OD'Brien BJ, Stoddart GL. Methods for the Economic Evaluation of Health Care Programmes, Oxford University Press, 2005.
6. Cervera R., Rúa-Figueroa I., Gil-Aguado A., Sabio J.M., Pallarés L., Hernández-Pastor L.J., et al. Direct cost of management and treatment of active systemic lupus erythematosus and its flares in Spain: the LUCIE Study. Rev Clín Esp 2013, 213:127-137.
7. Doria A., Amoura Z., Cervera R., Khamastha M.A., Schneider M., Richter J., et al. Annual direct medical cost of active systemic lupus erythematosus in five European countries. Ann Rheum Dis 2014, 73:154-160.
8. Cho J., Chang S., Shin N., Choi B., Oh H., Yoon M., et al. Costs of illness and quality of life in patients with systemic lupus erythematosus in South Korea. Lupus 2014, 23:949-957.
9. Aghdassi E., Zhang W., St-Pierre Y., Clarke A.E., Morrison S., Peeva V., et al. Healthcare cost and loss of productivity in a Canadian population of patients with and without lupus nephritis. J Rheumatol 2011, 38:658-666.
10. Meacock R., Dale N., Harrison M.J. The humanistic and economic burden of systemic lupus erythematosus: a systematic review. Pharmacoeconomics 2013, 31:49-61.
11. Garris C., Jhingran P., Bass D., Engel-Nitz N.M., Riedel A., Dennis G. Healthcare utilization and cost of systemic lupus erythematosus in a US managed care health plan. J Med Econ 2013, 16:667-677.
12. Khamashta M., Bruce I., Gordon C., Isenberg D., Ateka-Barrutia O., Gayed M., et al. The cost of care of systemic lupus erythematosus (SLE) in the UK: annual direct costs for adult SLE patients with active autoantibody-positive disease. Lupus 2014, 23:273-283.
13. Jönsen A., Bengtsson A.A., Hjalte F., Petersson I.F., Willim M., Nived O. Total cost and cost predictors in systemic lupus erythematosus-8-years follow-up of a Swedish inception cohort. Lupus 2015, 24:1248-1256.
14. Sturfelt G., Nived O. Clinical inconsistency, benign course and normal employment rates in unselected systemic lupus erythematosus. Clin Exp Rheumatol 1985, 3:303-310.
15. Gustafsson J.T., Gunnarsson I., Källberg H., Pettersson S., Zickert A., Vikerfors A., et al. Cigarette smoking, antiphospholipid antibodies and vascular events in Systemic Lupus Erythematosus. Ann Rheum Dis 2015, 74:1537-1543.
16. Ighe A., Dahlström Ö., Skogh T., Sjöwall C. Application of the 2012 systemic lupus international collaborating clinics classification criteria on a Regional Swedish systemic lupus erythematosus register. Arthritis Res Ther 2015, 17:3.
17. Bengtsson C., Ohman M.L., Nived O., Rantapää Dahlqvist S. Cardiovascular event in systemic lupus erythematosus in northern Sweden: incidence and predictors in a 7-year follow-up study. Lupus 2012, 21:452-459.
18. Leonard D., Svenungsson E., Sandling J.K., Berggren O., Jönsen A., Bengtsson C., et al. Coronary heart disease in systemic lupus erythematosus is associated with interferon regulatory factor-8 gene variants. Circ Cardiovasc Genet 2013, 6:255-263.
19. Gladman D., Ginzler E., Goldsmith C., Fortin P., Liang M., Urowitz M., et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996, 39:363-369.
20. Gladman D.D., Ibañez D., Urowitz M.B. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002, 29:288-291.
21. Drummond M.E., Sculpher M.J., Torrance G.W. Methods for the economic evaluation of health care programmes 2005, 379. Oxford University Press, Oxford; New York. 3rd ed.
22. Tan E.M., Cohen A.S., Fries J.F., Masi A.T., McShane D.J., Rothfield N.F., et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982, 25:1271-1277.
23. Panopalis P., Yazdany J., Gillis J.Z., Julian L., Trupin L., Hersh A.O., et al. Health care costs and costs associated with changes in work productivity among persons with systemic lupus erythematosus. Arthritis Rheum 2008, 59:1788-1795.
24. Kan H., Guerin A., Kaminsky M.S., Yu A.P., Wu E.Q., Denio A., et al. A longitudinal analysis of costs associated with change in disease activity in systemic lupus erythematosus. J Med Econ 2013, 16:793-800.
25. Clarke A.E., Urowitz M.B., Monga N., Hanly J.G. Costs associated with severe and non-severe SLE in Canada. Arthritis Care Res 2015, 67:431-436.
26. Furst D.E., Clarke A., Fernandes A.W., Bancroft T., Gajria K., Greth W., et al. Medical costs and healthcare resource use in patients with lupus nephritis and neuropsychiatric lupus in an insured population. J Med Econ 2013, 16:500-509.
27. Jönsen A., Bengtsson A.A., Nived O., Ryberg B., Sturfelt G. Outcome of neuropsychiatric systemic lupus erythematosus within a defined Swedish population: increased morbidity but low mortality. Rheumatol Oxf Engl 2002, 41:1308-1312.
28. Vogel A., Bhattacharya S., Larsen J.L., Jacobsen S. Do subjective cognitive complaints correlate with cognitive impairment in systemic lupus erythematosus? A Danish outpatient study. Lupus 2011, 20:35-43.
29. Pettersson S., Lövgren M., Eriksson L.E., Moberg C., Svenungsson E., Gunnarsson I., et al. An exploration of patient-reported symptoms in systemic lupus erythematosus and the relationship to health-related quality of life. Scand J Rheumatol 2012, 41:383-390.
30. Bexelius C., Wachtmeister K., Skare P., Jonsson L., Vollenhoven R.v. Drivers of cost and health-related quality of life in patients with systemic lupus erythematosus (SLE): a Swedish nationwide study based on patient reports. Lupus 2013, 22:793-801.
31. Statistics Sweden (SCB). Lönestatistik, 2011 [accessed 27.06.15]. http://www.scb.se.
32. Ekonomifakta. Sociala avgifter 2011, 2011 [accessed 27.06.15]. http://www.ekonomifakta.se.
33. European Central Bank currency exchange, 2011 [accessed 04.07.15]. https://sdw.ecb.europa.eu/curConverter.do.
34. Apotekens Service, Pharmaceutical Price Index, 2011 [accessed 04.07.15]. http://www.ehalsomyndigheten.se/Documents/statistik/standardrapporter/L%c3%a4kemedelsprisindex%201980-2009.pdf.
35. FASS, 2007 [accessed 04.07.15]. http://www.fass.se/LIF/healthcarefacts?docId=181063#document-top.